The price of CVS Health Corp (NYSE: CVS) closed at $59.64 in the last session, down -1.75% from day before closing price of $60.7. In other words, the price has decreased by -$1.75 from its previous closing price. On the day, 8.95 million shares were traded. CVS stock price reached its highest trading level at $61.13 during the session, while it also had its lowest trading level at $59.3509.
Ratios:
We take a closer look at CVS’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.93 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.70. For the most recent quarter (mrq), Quick Ratio is recorded 0.63 and its Current Ratio is at 0.82. In the meantime, Its Debt-to-Equity ratio is 1.06 whereas as Long-Term Debt/Eq ratio is at 0.96.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on February 13, 2025, Upgraded its rating to Outperform and sets its target price to $75 from $55 previously.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 05 ’25 when SANSONE GUY P bought 1,570 shares for $63.70 per share. The transaction valued at 100,009 led to the insider holds 12,007 shares of the business.
ROBBINS LARRY sold 2,276,068 shares of CVS for $154,444,758 on May 02 ’25. The Director now owns 9,670,731 shares after completing the transaction at $67.86 per share. On May 05 ’25, another insider, ROBBINS LARRY, who serves as the Director of the company, sold 1,323,932 shares for $67.41 each. As a result, the insider received 89,249,945 and left with 8,346,799 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CVS now has a Market Capitalization of 75445796864 and an Enterprise Value of 144185753600. As of this moment, CVS’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.25, and their Forward P/E ratio for the next fiscal year is 8.47. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.01. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.20 while its Price-to-Book (P/B) ratio in mrq is 0.98. Its current Enterprise Value per Revenue stands at 0.383 whereas that against EBITDA is 10.338.
Stock Price History:
The Beta on a monthly basis for CVS is 0.58, which has changed by -0.056030393 over the last 52 weeks, in comparison to a change of 0.17535925 over the same period for the S&P500. Over the past 52 weeks, CVS has reached a high of $72.51, while it has fallen to a 52-week low of $43.56. The 50-Day Moving Average of the stock is -7.34%, while the 200-Day Moving Average is calculated to be -1.79%.
Shares Statistics:
According to the various share statistics, CVS traded on average about 8.48M shares per day over the past 3-months and 7918020 shares per day over the past 10 days. A total of 1.27B shares are outstanding, with a floating share count of 1.26B. Insiders hold about 0.15% of the company’s shares, while institutions hold 86.72% stake in the company. Shares short for CVS as of 1752537600 were 13670187 with a Short Ratio of 1.61, compared to 1749772800 on 18713654. Therefore, it implies a Short% of Shares Outstanding of 13670187 and a Short% of Float of 1.09.
Dividends & Splits
The forward annual dividend rate for CVS is 2.66, which was 2.66 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 0.043822076The stock’s 5-year Average Dividend Yield is 3.13. The current Payout Ratio is 72.76% for CVS, which recently paid a dividend on 2025-07-22 with an ex-dividend date of 2025-07-22. Stock splits for the company last occurred on 2005-06-07 when the company split stock in a 2:1 ratio.
Earnings Estimates
As of right now, 23.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $1.44, with high estimates of $1.6 and low estimates of $1.15.
Analysts are recommending an EPS of between $6.5 and $6.01 for the fiscal current year, implying an average EPS of $6.12. EPS for the following year is $7.05, with 27.0 analysts recommending between $7.79 and $6.49.
Revenue Estimates
According to 19 analysts, the current quarter’s revenue is expected to be $94.59B. It ranges from a high estimate of $98.8B to a low estimate of $91.19B. As of the current estimate, CVS Health Corp’s year-ago sales were $91.23BFor the next quarter, 19 analysts are estimating revenue of $97.59B. There is a high estimate of $102.92B for the next quarter, whereas the lowest estimate is $95.18B.
A total of 24 analysts have provided revenue estimates for CVS’s current fiscal year. The highest revenue estimate was $402.31B, while the lowest revenue estimate was $381.65B, resulting in an average revenue estimate of $386.77B. In the same quarter a year ago, actual revenue was $372.81BBased on 23 analysts’ estimates, the company’s revenue will be $402.48B in the next fiscal year. The high estimate is $423.53B and the low estimate is $388.25B.
